Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

CompletedOBSERVATIONAL
Enrollment

96

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Multiple MyelomaNewly DiagnosedTransplant IneligiblePatient SatisfactionPatient PreferencePersonal Satisfaction
Interventions
BIOLOGICAL

Daratumumab

intravenous or subcutaneous

Trial Locations (1)

60389

Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main

All Listed Sponsors
lead

iOMEDICO AG

INDUSTRY